Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|4|2|150-160

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.4, Iss.2, 2011-04, pp. : 150-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 6-7

Bentham Science Publishers

Access to resources Recommend Favorite

177Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 85-93

Bentham Science Publishers

Access to resources Recommend Favorite

Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with 177Lu and Conjugated to Peptides

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 150-159

Bentham Science Publishers

Access to resources Recommend Favorite

Cellular Toxicity and Apoptosis Studies in Osteocarcinoma Cells, a Comparison of 177Lu-EDTMP and Lu-EDTMP

By  

Current Radiopharmaceuticals, Vol. 6, Iss. 3, 2013-09 ,pp. : 146-151

Bentham Science Publishers

Access to resources Recommend Favorite

A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu-DOTA-Nimotuzumab

By  

Current Radiopharmaceuticals, Vol. 5, Iss. 4, 2012-10 ,pp. : 318-324

Bentham Science Publishers

Access to resources Recommend Favorite